在接受免疫检查点抑制剂治疗的黑色素瘤患者中，女性发生皮肤不良事件的几率更高：一项回顾性队列研究。 - Suppr | 超能文献

相似文献

1

Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort study.在接受免疫检查点抑制剂治疗的黑色素瘤患者中，女性发生皮肤不良事件的几率更高：一项回顾性队列研究。

J Am Acad Dermatol. 2022 Aug;87(2):403-406. doi: 10.1016/j.jaad.2021.06.885. Epub 2021 Jul 10.

2

Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study.

Br J Dermatol. 2023 Oct 25;189(5):637-640. doi: 10.1093/bjd/ljad271.

3

Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma.晚期黑色素瘤患者接受免疫检查点抑制剂治疗期间血清乳酸脱氢酶与皮肤免疫相关不良事件的关联

J Am Acad Dermatol. 2022 Nov;87(5):1147-1149. doi: 10.1016/j.jaad.2022.02.024. Epub 2022 Feb 19.

4

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.抗程序性细胞死亡蛋白 1 抗体治疗与转移性黑色素瘤患者接受伊匹单抗免疫相关不良反应后毒性作用复发风险的相关性。

JAMA Dermatol. 2020 Sep 1;156(9):982-986. doi: 10.1001/jamadermatol.2020.2149.

5

Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.系统评价和荟萃分析抗 PD-1 进展的晚期黑色素瘤患者中免疫检查点抑制剂的疗效和安全性：系统评价和荟萃分析。

Clin Transl Oncol. 2021 Sep;23(9):1885-1904. doi: 10.1007/s12094-021-02598-6. Epub 2021 Apr 20.

6

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.免疫检查点抑制剂治疗的黑色素瘤患者血栓栓塞的发生率及其与生存的不良关联。

J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001719.

7

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.伊匹木单抗单药治疗或伊匹木单抗联合抗PD-1治疗转移性黑色素瘤患者对抗PD-(L)1单药治疗耐药：一项多中心、回顾性队列研究。

Lancet Oncol. 2021 Jun;22(6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11.

8

Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.免疫检查点抑制剂相关的免疫相关性甲状腺功能减退风险在老年晚期黑色素瘤患者中：来自美国 SEER-Medicare 数据的真实世界分析。

Expert Opin Drug Saf. 2021 Apr;20(4):489-497. doi: 10.1080/14740338.2021.1877272. Epub 2021 Jan 25.

9

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study.免疫检查点抑制剂相关白癜风及其对转移性黑色素瘤患者生存的影响：一项意大利黑色素瘤协作组研究

ESMO Open. 2021 Apr;6(2):100064. doi: 10.1016/j.esmoop.2021.100064. Epub 2021 Mar 10.

10

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.晚期黑色素瘤中伊匹单抗和非伊匹单抗治疗的长期真实世界经验：IMAGE 研究。

BMC Cancer. 2021 May 29;21(1):642. doi: 10.1186/s12885-021-08032-y.

引用本文的文献

1

Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses.免疫治疗毒性中的性别差异：对两性反应的见解。

Cancers (Basel). 2025 Mar 21;17(7):1054. doi: 10.3390/cancers17071054.

2

Medical dilemma: Programmed death 1 blockade (sintilimab) therapy in patients suffering from tumours combined with psoriasis.医学难题：程序性死亡1阻断（信迪利单抗）疗法用于合并银屑病的肿瘤患者。

World J Cardiol. 2024 Sep 26;16(9):546-549. doi: 10.4330/wjc.v16.i9.546.

3

Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications.